Pharmaceutical Patent Litigation

We understand the advancements in life sciences that are shaping the IP landscape and excel at handling the most complex, bet-the-company cases. Our litigation experience covers a wide variety of conditions, from dry eye and gastrointestinal disease to cancer and psychological disorders. We are also experienced with a broad list of products, ranging from topical emulsions to therapeutic antibodies. In addition, we manage cases involving related technology such as DNA sequencing and drug delivery devices.

Tailored Legal Strategies

Whether you are anticipating generic or biosimilar competition for key products, or contemplating a generic or biosimilar product launch, we understand the sophisticated IP issues that can arise in litigation. Our lawyers have particular depth of experience at the interface between patent law and the Food and Drug Administration’s (FDA) drug approval process. We excel at every phase of the ANDA or BPCIA process, helping innovators or companies contemplating generics or biosimilars to achieve their commercial objectives. Our team develops strong positions early in litigation, preparing a detailed case roadmap to identify essential discovery, and drive discovery to fill gaps in that roadmap. We have litigated cases involving formulations, methods of treatment, label carve-outs, and more.

Leaders Across Trial Venues

We are particularly skilled at coordinating actions across multiple venues when a multi-venue strategy can be favorable for our clients, including in federal district and appellate courts and the International Trade Commission. We also collaborate with our Post-Grant Practice Group to challenge patents in inter partes review and post-grant proceedings before the Patent Trial and Appeal Board.